Posted by Roquette {oosts Extensive Cyclodextrins Portfolio with Launch of KLEPTOSE® Crysmeb Methyl-Beta-Cyclodextrin for Oral and Parenteral Formulations
In contrast to DIMEB or RAMEB forms of methylated cyclodextrin, KLEPTOSE® Crysmeb is suitable for both oral and parenteral delivery methods, allowing drug manufacturers greater freedom to adapt for therapeutic efficacy and patient preference. This flexibility makes KLEPTOSE® Crysmeb an ideal solution for drug development and optimization, blending safety and formulation performance.
KLEPTOSE® Crysmeb is a unique MßCD in which most of the methyl groups are attached at the C2 position on the glucose chains that make up cyclodextrins’ distinctive ring-shaped molecules. This specific substitution pattern significantly increases the aqueous solubility of the modified cyclodextrin, allowing it to form soluble inclusion complexes with poorly soluble APIs such as those used in Class II and IV drugs. The excellent encapsulation capacity of KLEPTOSE® Crysmeb makes it an equally powerful stabilizer, protecting sensitive actives from degradation due to temperature fluctuations encountered during production and supply chain.